Regeneron receives FDA’s EUA approval for its COVID-19 drug

By: Miguel A. Rodriguez

17:11, 23 November 2020

The FDA grants EUA for Regeneron’s treatment taken by President Trump

After a week when giant pharma companies such as Moderna, Pfizer, and AstraZeneca announced that their experimental COVID-19 vaccines are effective in preventing the infection, another company filed for FDA’s approval.

The drug developed by Regeneron has received earlier today the emergency use authorization (EUA) from the Food and Drug Administration. It is the same drug that Trump used when he contracted the virus.

According to studies, Regeneron’s vaccine is effective when administrated shortly after diagnosis. The authorization allows it to be used on patients who are at risk of severe illness.

By the end of November, Regeneron will have doses for roughly 80,000 patients. By the end of January 2021, it will have doses available for 300,000 people.

The number of COVID-19 continues to rise; at the moment of writing, the US has more than 12 million confirmed cases.

After the news, Regeneron stock price went up 3.9%.

Read here about AstraZeneca’s progress!


Share this article

This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.